Eli Lil­ly's an­ti­body cuts risk of Covid-19 by up to 80% among the most vul­ner­a­ble — but will it have a place next ...

5 years ago
R&D
Coronavirus

End­points poll: Janet Wood­cock takes the (in­ter­im) helm at the FDA. And a large ma­jor­i­ty of our read­ers want her to ...

5 years ago
People
FDA+

With patent con­cerns loom­ing, Roche gets a new pri­or­i­ty re­view on block­buster IPF drug

5 years ago
R&D

BIO looks to re­struc­ture, lay­ing off staff amid chal­lenge to the trade org's nor­mal face-to-face style

5 years ago
Pharma

What’s next for End­points — and how to sup­port our in­de­pen­dent bio­phar­ma news mis­sion

5 years ago
Publisher's note

FDA guides on Covid-19 con­sid­er­a­tions in cell and gene ther­a­py

5 years ago
FDA+

Once laser-fo­cused on liv­er, Mi­NA takes swing at neu­rol­o­gy with Servier's back­ing

5 years ago
Deals

Pieris fi­nal­ly vaults FDA hold on next-gen sol­id tu­mor hunter, clear­ing the path for mid-stage tri­al

5 years ago
FDA+

News brief­ing: Ve­rastem CMO ex­its two weeks af­ter join­ing com­pa­ny; Ther­mo Fish­er inks $550M M&A deal

5 years ago
News Briefing

FDA hits the brakes on His­to­gen's knee car­ti­lage ther­a­py, ask­ing for more in­fo on man­u­fac­tur­ing process

5 years ago
FDA+

Grit­stone con­tin­ues Covid-19 push with deal to de­vel­op 'self-am­pli­fy­ing RNA' vac­cines, as shares con­tin­ue bal­loon­ing

5 years ago
Deals
Coronavirus

Bris­tol My­ers Squibb gets re­view date for Op­di­vo com­bo in gas­tric can­cer, look­ing to over­turn Keytru­da's 3-year lead

5 years ago
FDA+

Covid-19 claims an­oth­er PDU­FA vic­tim as Glax­o­SmithK­line push­es back planned PD-1 roll­out

5 years ago
FDA+

Bio­Med Re­al­ty snaps up in­no­va­tion cam­pus site with­in earshot of pricey and bustling Boston biotech hub

5 years ago
Pharma

Glax­o­SmithK­line's $4B bis­pe­cif­ic can­cer drug al­liance with Mer­ck KGaA hit by big set­back with a PhI­II fail­ure on ...

5 years ago
R&D

Paul Hud­son faces down French unions in fight to re­struc­ture Sanofi

5 years ago
Pharma

The IPO flood keeps ris­ing with 4 more biotechs and a SPAC on their way to Nas­daq

5 years ago
Financing

Covid-19 roundup: BioN­Tech of­fers da­ta show­ing Pfiz­er-part­nered vac­cine pro­tects against vari­ant; No­vavax at­trib­ut­es ...

5 years ago
Coronavirus

Mer­ck makes good on big CV gam­ble with veri­ciguat nod — but com­pe­ti­tion will be fierce

5 years ago
FDA+

As he wraps stormy FDA tenure, Hahn ad­mits 'there was a sub­stan­tial amount of pres­sure' from White House — re­port

5 years ago
People

HHS, FDA dis­pute spills out on­to Twit­ter

5 years ago
FDA+

The IPO queue adds 5 more biotechs hop­ing to ring in 2021 by blitz­ing Nas­daq

5 years ago
Financing

News brief­ing: Beam bags a $260M pri­vate place­ment; mi­Ra­gen re­brands to Virid­i­an Ther­a­peu­tics

5 years ago
News Briefing

As­traZeneca keeps the ball rolling on Dai­ichi-part­nered En­her­tu, pick­ing up 2nd in­di­ca­tion in gas­tric can­cer

5 years ago
Pharma
FDA+
First page Previous page 745746747748749750751 Next page Last page
A service from the Financial Times